{"entity":{"id":"bi-1607","kind":"drug","name":"BI-1607","aka":[],"tldr":"BI-1607 is an experimental monoclonal antibody from BioInvent International, in phase 2 trials for melanoma, uveal melanoma and HER2-positive breast cancer and other cancers.","summary":"BI-1607 is a monoclonal antibody (engineered) from BioInvent International. An engineered anti-FcγRIIB (FCGR2B) antibody intended to enhance efficacy and overcome resistance to existing cancer treatments such as targeted antibodies and checkpoint inhibitors; tested with ipilimumab and pembrolizumab in melanoma and earlier with trastuzumab. Its furthest stage is phase 2, for melanoma, uveal melanoma, HER2-positive breast cancer and HER2-positive gastric cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1b/2a NCT06784648 (melanoma, with ipilimumab and pembrolizumab) active, not recruiting; the earlier trastuzumab combination trial NCT05555251 is terminated (registry, checked 3 Nov 2026). The BI-1607 page is no longer linked from BioInvent's programme menu. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"BioInvent International: bioinvent.com","url":"https://www.bioinvent.com/en/clinical-programs/our-programs/bi-1607"},{"label":"BioInvent International: bioinvent.com","url":"https://www.bioinvent.com/en"},{"label":"ClinicalTrials.gov: trials of BI-1607","url":"https://clinicaltrials.gov/search?intr=BI-1607"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","uveal-melanoma","breast-her2-positive","gastric-her2-positive"],"sections":[],"technologies":[],"targets":["fcgr2b"],"drugs":[],"companies":["bioinvent-international"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06784648","nct05555251"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"BI-1607","modality":"Monoclonal antibody (engineered)","mechanism":"An engineered anti-FcγRIIB (FCGR2B) antibody intended to enhance efficacy and overcome resistance to existing cancer treatments such as targeted antibodies and checkpoint inhibitors; tested with ipilimumab and pembrolizumab in melanoma and earlier with trastuzumab.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bi-1607/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"gastric-her2-positive","kind":"cancer","name":"HER2-positive gastric cancer","route":"/cancers/gastric-her2-positive/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"target":[{"id":"fcgr2b","kind":"target","name":"FCGR2B","route":"/targets/fcgr2b/"}],"company":[{"id":"bioinvent-international","kind":"company","name":"BioInvent International","route":"/companies/bioinvent-international/"}],"trial":[{"id":"nct05555251","kind":"trial","name":"BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors","route":"/trials/nct05555251/"},{"id":"nct06784648","kind":"trial","name":"Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma","route":"/trials/nct06784648/"}]}}